Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
Titel:
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
Auteur:
Cameron, David Morden, James P Canney, Peter Velikova, Galina Coleman, Robert Bartlett, John Agrawal, Rajiv Banerji, Jane Bertelli, Gianfilippo Bloomfield, David Brunt, A Murray Earl, Helena Ellis, Paul Gaunt, Claire Gillman, Alexa Hearfield, Nicholas Laing, Robert Murray, Nicholas Couper, Niki Stein, Robert C Verrill, Mark Wardley, Andrew Barrett-Lee, Peter Bliss, Judith M
Verschenen in:
Lancet oncology
Paginering:
Jaargang 18 (2017) nr. 7 pagina's 929-945
Jaar:
2017
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license